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Selenoproteins are central controllers of cellular redox homeostasis. Incorporation of selenocysteine (Sec)
into selenoproteins employs a unique mechanism to decode the UGA stop codon. The process requires the Sec
insertion sequence (SECIS) element, tRNASec, and protein factors including the SECIS binding protein 2
(SBP2). Here, we report the characterization of motifs within SBP2 that regulate its subcellular localization
and function. We show that SBP2 shuttles between the nucleus and the cytoplasm via intrinsic, functional
nuclear localization signal and nuclear export signal motifs and that its nuclear export is dependent on the
CRM1 pathway. Oxidative stress induces nuclear accumulation of SBP2 via oxidation of cysteine residues
within a redox-sensitive cysteine-rich domain. These modifications are efficiently reversed in vitro by human
thioredoxin and glutaredoxin, suggesting that these antioxidant systems might regulate redox status of SBP2
in vivo. Depletion of SBP2 in cell lines using small interfering RNA results in a decrease in Sec incorporation,
providing direct evidence for its requirement for selenoprotein synthesis. Furthermore, Sec incorporation is
reduced substantially after treatment of cells with agents that cause oxidative stress, suggesting that nuclear
sequestration of SBP2 under such conditions may represent a mechanism to regulate the expression of
selenoproteins.
Organisms growing in the presence of oxygen are continu-
ously exposed to oxidative challenge caused by reactive oxygen
species (ROS) generated either endogenously through oxygen
metabolism or exogenously from environmental stress. Changes
in the intracellular redox state lead to protein modifications
which in turn affect protein function, interactions, and sub-
cellular localization (43). Upon oxidation, cysteine residues
within proteins can be modified to different products, including
reversible inter- or intramolecular disulfide bonds (S-S), glu-
tathione-mixed disulfides (S-SG), S-nitrosothiols (S-NO), and
sulfenic acids (S-OH), or to the irreversible forms of sulfinic
(S-O2H), and sulfonic (S-O3H) acids. Protein disulfides and
glutathione-mixed disulfides are, however, thought to be the
predominant means of redox modifications within mammalian
cells (25, 48). The intracellular redox homeostasis is main-
tained by the concerted action of antioxidant systems, includ-
ing thioredoxin (Trx) and thioredoxin reductases (TR), glu-
taredoxins (Grx), glutathione peroxidases and glutathione
reductases (GR), catalase, superoxide dismutase, and the tri-
peptide glutathione (L--glutamyl-L-cysteinylglycine [GSH])
(26, 35). Members of the antioxidant defense systems include
the selenoproteins TR and glutathione peroxidase, which use
the redox potential of selenium existent in their catalytic site.
In addition, selenoproteins function in thyroid hormone me-
tabolism, transport, and distribution of selenium to remote
tissues and have roles as structural proteins (27).
Selenium is cotranslationally incorporated into selenopro-
teins in the form of the nonstandard amino acid selenocysteine
(Sec). Since Sec is encoded by the UGA codon, which most
frequently serves as a termination codon, its translation entails
a unique decoding process (41). One of the features that dic-
tates Sec incorporation is the Sec insertion sequence (SECIS)
element, which in eukaryotes is located in the 3 untranslated
region of selenoprotein mRNAs (5, 6). In addition, several
trans-acting factors are involved in the process, including the
selenocysteine-specific tRNA, tRNA[Ser]Sec (40, 41); the eu-
karyotic Sec-specific elongation factor, eEFsec (20, 51); and
SECIS binding protein 2 (SBP2) (11). The list of protein fac-
tors involved in this mechanism is constantly growing, the most
recent members being the ribosomal protein L30 (10), soluble
liver antigen, and SECp43 (55).
Despite recent progress in the selenoprotein field, under-
standing the regulation of selenoprotein synthesis is still in the
early phases of discovery. It was recently suggested that Sec
incorporation may be inherently inefficient, and a rate-limiting
factor has not yet been identified in vivo (45). Current evidence
has been somewhat conflicting regarding which of the so-far-
identified factors is limiting for selenoprotein synthesis in cell
culture models (15). SBP2 is one of the oldest and best-char-
acterized factors in this process, which was shown to bind
directly to SECIS elements via its L30-type RNA binding do-
main. SBP2 was shown to be essential for Sec incorporation in
an in vitro model (12, 13); however, its requirement in vivo has
not yet been determined. SBP2 is proposed to function by
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recruiting the eEFsec-tRNASec complex to the ribosome (51)
and seems to play a role in dictating Sec incorporation effi-
ciency (44, 56). Interestingly, a recent study found that inher-
ited mutations within SBP2 result in abnormal thyroid hor-
mone metabolism (16), representing the first direct link
between SBP2 and human disease.
One aspect of SBP2 regulation that has not been thoroughly
addressed has been its subcellular localization in cells. A strong
putative nuclear localization signal (NLS) within the SBP2
primary amino acid sequence was reported early on (12), lead-
ing to the hypothesis that SBP2 may translocate through the
nuclear compartment. However, in later studies, endogenous
SBP2 was detected solely in the ribosomal fraction of cells (13,
38) and overexpressed SBP2 was detected within the cytoplasm
of cells (45), generating confusion about the localization of
SBP2 in cells.
The nuclear or cytoplasmic localization of a protein at any
one time depends on the relative rate of nuclear import and
export, which may in turn be regulated by the intracellular
conditions. This requires the presence of conserved signal se-
quences such as the NLS and the nuclear export signal (NES)
within shuttling proteins, which are recognized by specific re-
ceptors and adaptors (18). Transport of proteins into the nu-
cleus is mediated by interactions between members of the
importin superfamily of transport proteins and NLSs within
cargo proteins (37). The best-characterized pathway for nu-
clear export of proteins involves the nuclear export receptor
CRM1, which binds directly to NESs and enables the translo-
cation of proteins from the nucleus into the cytoplasm (24, 50).
In the present study, we further investigated the localization
of SBP2 and report the identification of sequence elements
required for nucleocytoplasmic trafficking of SBP2. SBP2 is
localized predominantly at the ribosomal sites due to dominant
nuclear export signals. SBP2 is depleted from ribosomes and
becomes nuclear upon inhibition of CRM1 or after treatment
of cells with oxidative stress-causing agents. This nuclear se-
questration of SBP2 is associated with a concomitant decrease
in selenoprotein synthesis. Consistent with this, we show that
SBP2 is a redox-sensitive protein that forms inactivating disul-
fide bonds and glutathione-mixed disulfides in response to
oxidative stress and that the redox status of SBP2 is regulated
through the thioredoxin and the glutaredoxin systems. Small
interfering RNA (siRNA)-mediated depletion of SBP2 results
in decreased selenoprotein synthesis, providing direct evidence
for the requirement of SBP2 for incorporation of Sec. Due to
lack of efficient selenoprotein synthesis, cells depleted of SBP2
are more sensitive to oxidative stress, suggesting that SBP2 is
central to protection against oxidative damage.
MATERIALS AND METHODS
Plasmid construction. Full-length SBP2 cDNA was produced in two stages. A
partial human SBP2 cDNA (AL136881) lacking the 5 end was obtained as a kind
gift of the German Cancer Research Centre (DKFZ), Berlin, Germany. This
sequence was subcloned into the EcoRI/SalI sites of the enhanced green fluo-
rescent protein (EGFP)-N1 vector (Clontech). The missing 5 sequence was
generated by PCR using Pfu polymerase from the 293T cell line, and the result-
ing product was subcloned into the existing EGFP-N1 plasmid using the EcoRI/
BclI sites (SBP2-GFP). Deletion constructs NLS-GFP (amino acids [aa] 1 to 583,
bp 1 to 1751) and NES-GFP (aa 84 to 854, bp 1752 to 2562) were generated by
PCR from the full-length SBP2-GFP plasmid and subcloned into the EGFP-N1
vector using the EcoRI/SalI sites. The NLS mutant (383K3A/K3843A) was
generated within SBP2-GFP by site-directed mutagenesis using the Quick-
Change kit (Stratagene) following the supplier’s protocol. For the in vivo NES
assay, double-stranded oligonucleotides encoding the amino acid sequence of
candidate SBP2 NESs (described in Fig. 2E) were cloned into the pRev(1.4)-
GFP plasmid (29) using the BamHI site and screened for orientation by sequenc-
ing. For in vitro studies, the carboxy-terminal SBP2 (aa 584 to 854) was cloned
into pET24a (Novagen) using the XhoI and NheI restriction sites. For SBP2
siRNA, the sequence AAAATCAAGCTAGAGGTTCACA was cloned into the
pSUPER vector (a gift of Reuven Agami, The Netherlands Cancer Institute,
Amsterdam) and transfected into cells alongside pSuper-GFP as a control (19).
Cell culture, treatments, and transfections. Cells were maintained at 37°C in
a 5% CO2 incubator and cultured in RPMI 1640 medium supplemented with 3%
fetal bovine serum (GIBCO-BRL) and 7% Serum Supreme (Cambrex), 1%
L-glutamine, and 100 U/ml penicillin and streptomycin. H2O2 treatments were
performed in serum-free medium at a final concentration of 300 M, unless
otherwise indicated. Cells were exposed to 5, 10, or 20 J/m2 type A UV (UVA)
irradiation in phosphate-buffered saline (PBS) and allowed to recover in com-
plete medium for 2 h. Leptomycin B (LMB) was kindly supplied by M. Yoshida
(Department of Biotechnology, University of Tokyo, Tokyo, Japan) and added to
culture medium at a final concentration of 2 ng/ml. Actinomycin D (Act D)
(ICN) was dissolved in ethanol and was used at a final concentration of 5 g/ml.
Cycloheximide (Sigma) was added to cells from a stock solution in dimethyl
sulfoxide at a final concentration of 15 g/ml. COS7 cells plated on coverslips in
six-well plates 24 h before were transfected with 1 g/well of plasmid DNA using
the FuGene (Roche) reagent according to the manufacturer’s instructions.
Fluorescence microscopy. Cells transfected with GFP-tagged proteins were
washed in PBS twice and fixed with 4% paraformaldehyde in PBS for 30 min at
room temperature. 4,6-Diamidino-2-phenylindole(DAPI) was used to stain the
nuclei. Coverslips were mounted with polyvinyl alcohol (Mowiol; Calbiochem)
containing 0.6% DABCO (diazobicyclo-octane) and visualized on an inverted
fluorescent microscope (IM 1000; Leica).
Generation of anti-SBP2 antibodies. A highly antigenic region within the
SBP2 sequence (aa 279 to 378) was subcloned into the pGEX-4T1 (Pharmacia)
expression vector using the EcoRI and XhoI restriction sites. Recombinant
protein was purified from Escherichia coli following standard procedures. Two
Dutch belted (Oryctolagus cuniculus) rabbits were immunized with 500 g of the
purified glutathione S-transferase (GST) fusion protein suspended in the Sigma
MPLTDMCWS (monophosphoryl-lipid A plus trehalose dicorynomycolate
plus cell wall skeleton) adjuvant system, which was prepared according to the
supplier’s instructions. Intradermal and intramuscular injections were performed
at week 1, followed by intradermal injections at weeks 3, 6, and 9. Blood was
collected at weeks 0 (preimmune serum), 5, 10, and 13 (final bleeding by heart
puncture), and serum was separated. Polyclonal antibodies against SBP2 were
affinity purified from rabbit sera by chromatography through GST-coupled
CNBr-activated Sepharose 4B columns (Pharmacia) to remove antibodies
against GST, followed by chromatography of the unbound fraction on CNBr-
activated Sepharose 4B columns bound with SBP2-fusion protein used for im-
munization. Antibodies were eluted with Tris-glycine buffer (pH 2.6) and dia-
lyzed against PBS. The final antibody concentration obtained was 1 mg/ml.
Cell lysis, immunoprecipitation, and Western blot analysis. Cell extracts were
prepared by lysis in universal immunoprecipitation (UIP) buffer (50 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 25 mM -glycero-
phosphate, 0.2% Triton X-100, and 0.3% NP40) supplemented with 25 mM
sodium fluoride, 25 mM sodium orthovanadate, and protease inhibitor cocktail
(Sigma). Total cell lysate (40 g/lane) was resolved by 8% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Im-
mobilon-P membranes (Millipore). SBP2 was detected with affinity-purified rab-
bit polyclonal antibodies at a 1:2,000 dilution in 10% skim milk powder in
PBS-Tween 20 (PBST). Anti-RNA polymerase II (Pol II) antibodies (Santa
Cruz) were used at a 1:1,000 dilution, antiactin antibodies (Sigma; A-2066) at a
1:500 dilution, and anti-PCNA antibodies (Santa Cruz) at a 1:1,000 dilution.
Proteins were detected by chemiluminescence (Perkin-Elmer). Immunoprecipi-
tation was carried out in UIP buffer using 1 g anti-SBP2 antibodies/mg protein
and protein G-Sepharose beads (Amersham) according to the manufacturer’s
protocol.
Subcellular fractionation. Subcellular fractions were prepared by a differential
centrifugation method (2). Briefly, 5  106 293T cells grown in 100-mm2 culture
dishes were scraped into phosphate-buffered saline containing 1 mM EDTA and
centrifuged at 750  g for 10 min, washed, and suspended in mitochondrial
buffer (MB) (210 mM mannitol, 70 mM sucrose, 1 mM EDTA, 10 mM HEPES-
NaOH, pH 7.5) complemented with protease inhibitors. Cells were disrupted by
passing through a 26G needle five times followed by centrifugation at 2000  g
for 5 min. This pellet represented the nuclear fraction. The supernatant was
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subsequently centrifuged at 13,000  g for 10 min to yield the mitochondrial
pellet. The supernatant was further centrifuged at 100,000  g for 30 min to yield
the microsomal pellet containing endoplasmic reticulum and other organelles
and centrifuged again at 300,000  g for 16 h to yield the free cytosolic ribo-
somes. All pellets were resuspended in equal volumes of UIP lysis buffer con-
taining 2 mM dithiothreitol (DTT), and equal volumes of each fraction, unless
otherwise indicated, were loaded on SDS-PAGE for subsequent analysis.
In vivo NES assay. Analysis of candidate SBP2 NESs was carried out as
described previously (29). Briefly, Rev1.4-GFP fusion proteins containing SBP2-
NES sequences were expressed in COS7 cells and analyzed by fluorescence
microscopy in untreated cells or after 3 h of treatment with either LMB or Act
D cotreated with cycloheximide.
Determination of the SBP2 redox state in vivo. 293T cells were treated with
oxidants as described above. Iodoacetamide (IAM) at a final concentration of 30
mM was added to cells 20 min prior to harvest to irreversibly alkylate all free
thiols in vivo. Cells were washed twice in PBS and lysed in UIP buffer. Residual
IAM was removed by passing lysates through a G-25 desalting column (Amer-
sham). Lysates were incubated with 3.5 mM DTT at room temperature for 30
min to reduce any in vivo-formed disulfide bonds and subsequently passed
through a G-25 column to remove DTT. Newly reduced thiols were alkylated
with biotin-conjugated IAM (BIAM) at 37°C for 30 min. SBP2 was subsequently
immunoprecipitated, resolved by SDS-PAGE, and transferred to polyvinylidene
difluoride membrane. Membranes were first probed with horseradish peroxidase
(HRP)-conjugated streptavidin (Molecular Probes) to detect BIAM-alkylated
protein, stripped, and reprobed with anti-SBP2 antibodies for total SBP2.
75Se and [35S]methionine labeling. HeLa cells were plated onto 10-cm dishes
and incubated for 24 h. Where indicated, cells were incubated in the presence of
LMB (2 ng/ml) for 16 h or H2O2 as described above. Treatment medium was
replaced with fresh complete medium supplemented with 50 nM sodium selenite
and 10 Ci 75Se per dish. 75Se was obtained as selenious acid from the Research
Reactor Facility (University of Missouri, Columbia). For 35S labeling, medium
was changed to methionine-free RPMI medium containing dialyzed fetal calf
serum 1 h prior to addition of 100 Ci [35S]methionine (Amersham). Labeling
was conducted for 24 h in the presence or absence of LMB. In siRNA experi-
ments, HeLa cells were transfected with siRNA SBP2 and control plasmids and
incubated for 72 h to reach maximal SBP2 knockdown. At 72 h posttransfection,
cells (70% confluent) were treated with H2O2 and labeled with 75Se as de-
scribed above. Cells were harvested 24 h later and lysed in UIP buffer. Proteins
were resolved by SDS-PAGE and analyzed by autoradiography. Densitometry of
radioactive signals was performed using the MultiGauge v2.3 software.
Determination of free thiol content and reduction of oxidized six-His-tagged
NES (NES-His6) by Trx in vitro. The number of free thiols in the oxidized and
reduced NES-His6 proteins was determined by dithionitrobenzoate (DTNB)
assay as described previously (59). Reduction of oxidized NES-His6 by thiore-
doxin was measured as previously described (33).
Reduction of glutathionylated NES-His6 by glutaredoxin 1 in vitro. A 78 M
concentration of NES-His6 was reduced with 10 mM DTT at 37°C for 30 min,
then DTT was removed by Sephadex G-25 desalting column. The reduced pro-
tein was incubated with 100 mM oxidized GSH (GSSG) at 37°C for 2 h and
passed through Sephadex G-25 column to remove free GSSG. Reduction by
human Grx1 was measured as described previously (36).
Fluorescence emission spectra. DTT-reduced Trx (0.1 M) in nitrogen equil-
ibrated Tris-EDTA (TE) buffer was mixed with oxidized NES-His6 (0.1 M). A
thermostatic SPEX-FluoroMax spectrofluorometer was employed to measure
the fluorescence as previously described (58). The fluorescence spectra of oxi-
dized Trx were obtained by subtracting the value of oxidized NES-His6 alone
from the value of the mixture of reduced Trx with oxidized NES-His6.
Mass spectrometry of glutathionylated NES-His6. Glutathionylated NES-His6
was prepared as described above and denatured by 8 M guanidinium chloride at
37°C. Denatured protein was diluted 10 times with 10 mM ammonium bicar-
bonate, pH 7.6, and cleaved by endoproteinase Glu-C (Roche) for 2 h. A
Voyager De-PRO matrix-assisted laser desorption ionization (MALDI) mass
spectrometer (Applied Biosystems) was used to detect the peptide mass of the
complex.
Cell viability assay. Cell viability was analyzed using the XTT [2,3-bis(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxyanilide] cell prolifera-
tion kit II (Roche). HeLa cells were transfected with siRNA SBP2 or siRNA
GFP plasmids. Forty-eight hours after transfections, cells were detached and
plated at a density of 4  104 cells/well in 96-microwell plates and allowed to
grow in the normal growth medium for 24 h. H2O2 and sodium selenite treat-
ments were applied to cells in 96-microwell plates in a serial dilution, and
incubation was conducted for another 20 h. The XTT reagent (50 l/well) was
added, and plates were read at 475 nm in a Benchmark Plus microplate reader
at 3, 6, and 20 h of XTT incubation. Data points were plotted using the Microsoft
Excel program and analyzed for statistical significance using a one-way analysis
of variance test.
RESULTS
SBP2 shuttles between the nucleus and the cytoplasm via
the CRM1 pathway. To initiate our studies of SBP2 subcellular
localization, we generated a plasmid for expression of GFP-
tagged SBP2 in mammalian cells. Localization of the SBP2-
GFP fusion protein was determined by fluorescence micros-
copy after transient expression into various cell types, including
COS7, 293T, and HeLa cells. In line with previous observations
(45), SBP2-GFP was localized predominantly within the cyto-
plasm of COS7 cells (Fig. 1A, left panel) and other cells tested
(data not shown), despite the presence of a conserved, putative
NLS within its amino terminus. Detailed SBP2 amino acid
sequence analysis revealed the existence of five putative NESs,
reminiscent of the NES identified within the human immuno-
deficiency virus Rev protein (53), which prompted us to inves-
tigate the possibility that SBP2 shuttles between the nucleus
and the cytoplasm. Treatment of cells with LMB, a CRM1-
specific inhibitor (54), results in nuclear accumulation of pro-
teins that are exported from the nucleus in an NES-dependent
manner, via the CRM1 pathway. We first determined the effect
of LMB on the subcellular distribution of overexpressed SBP2-
GFP, which within 2 h of treatment showed an almost com-
plete nuclear accumulation in COS7 cells (Fig. 1A, right panel)
and other cells tested (data not shown). This suggested that
SBP2-GFP may contain at least one functional NES, which
facilitates its continuous shuttling between the nucleus and the
cytoplasm; however, constitutive export by CRM1 confines the
steady-state protein localization to the cytoplasm. GFP alone
did not respond to the LMB treatment (Fig. 1A, bottom pan-
els). Quantitation of the subcellular distribution of SBP2-GFP
(Fig. 1B) showed that LMB treatment significantly increased
the proportion of cells with nuclear fluorescence, consequently
decreasing the number of cells with cytoplasmic fluorescence.
We next investigated the subcellular distribution of endog-
enous SBP2 in cells using a polyclonal anti-SBP2 antibody
raised in house. Figure 1C shows that the antibodies specifi-
cally recognize overexpressed SBP2-GFP and the endogenous
120-kDa SBP2 protein. Since the anti-SBP2 antibodies did not
show specificity for use in immunofluorescence microscopy,
subcellular fractionation and Western blotting were employed
to determine the intracellular distribution of endogenous
SBP2. Consistent with previous reports (13, 38), we observed
that SBP2 is present in the ribosomal and the endoplasmic
reticulum-containing fractions of 293T cells (Fig. 1D). RNA
polymerase II and actin were used as markers for the nuclear
and cytosolic compartments, respectively, confirming a mini-
mal cross-contamination between the compartments. Since
SBP2-GFP was found to be continuously exported from the
nucleus by CRM1, we postulated that only a small proportion
of endogenous SBP2 may be present within the nuclei of cells
at any one time. To address this question, we concentrated the
nuclear and cytosolic fractions and quantified the amount of
SBP2 by comparing it to the amount in the ribosomal fraction.
Interestingly, some SBP2 was indeed present within the nu-
clear, but not the cytosolic fraction (Fig. 1D, right panel).
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FIG. 1. SBP2 shuttles between the nucleus and the cytoplasm via the CRM1 pathway. (A) COS7 cells were transiently transfected with
full-length human SBP2 fused to GFP or GFP vector alone, and representative microscopy images are shown with (right panels) or without (left
panels) LMB treatment (2 ng/ml). DAPI-stained DNA is shown, and arrows indicate transfected cells. (B) Graphical representation of the
percentage of cells showing changes in distribution of SBP2-GFP upon LMB treatment. Fluorescent cells were scored as either nuclear (N),
cytoplasmic (C), or nuclear/cytoplasmic (N/C). Values represent the mean of three independent experiments. A minimum of 200 cells were
counted per experiment. (C) Western blot (WB) analysis shows specific recognition of overexpressed SBP2-GFP at 150 kDa (lane 2) and
endogenous SBP2 at 120 kDa (lanes 1 and 2) by the anti-SBP2 polyclonal antibodies at a 1:2,000 dilution. (D) Subcellular fractionation of 293T
cells. SBP2 was detected as described in panel C. RNA Pol II at a 1:1,000 dilution and actin at a 1:500 dilution were used as markers for the nuclear
and cytosolic compartments, respectively. The nuclear and cytosolic fractions were concentrated 5 times (5x conc.), and SBP2 was quantified by
comparing it to the original ribosomal (Ribos.) fraction (right panel). The amount of SBP2 as estimated by densitometry is indicated as a
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Using densitometry analysis, we estimate that under the cur-
rent experimental conditions, in 293T cells 60% of the total
SBP2 pool was present within the cytosolic ribosomes, 30%
within the organelles, which may represent the endoplasmic
reticulum-attached ribosomes, and 10% within the nuclei.
These results suggest that the localization of SBP2 is dynamic,
not solely confined to ribosomal sites, and that SBP2 does
translocate through the nuclear compartment, possibly by us-
ing the predicted NLS.
To further analyze the shuttling properties of endogenous
SBP2, nuclear extracts were prepared from untreated or LMB-
treated HeLa cells. Importantly, Western analysis confirmed
the above results, showing that endogenous SBP2 relocates
from the ribosomes to the nucleus upon LMB treatment (Fig.
1E, top panels), however, with slower kinetics than overex-
pressed SBP2-GFP as the accumulation required a 16-h treat-
ment. The nuclear translocation is not due to cell stress or
apoptosis in response to unusually long treatment with LMB,
since the treatment did not affect the proliferation rate or the
viability of cells (data not shown). One possible explanation for
this discrepancy is that there is a significant pool of overex-
pressed SBP2-GFP not bound to ribosomes and therefore free
in the cytosol to continuously shuttle between the two com-
partments. In contrast, the endogenous pool of SBP2 remains
stably associated with ribosomes and its nuclear localization
may be tightly regulated and only triggered by certain condi-
tions or stimuli.
We next investigated the effect of SBP2 localization on Sec
incorporation in cells by 75Se labeling in the presence or ab-
sence of LMB. Interestingly, LMB treatment led to a twofold
decrease in Sec incorporation, which could be potentially at-
tributed to the depletion of SBP2 from the ribosomes and its
accumulation in the nucleus (Fig. 1F, left panels). Since LMB
treatment inhibits the CRM1 nuclear export pathway and
other general translation factors use this pathway to shuttle in
and out of the nucleus (8), we measured the effects of LMB on
general protein synthesis by [35S]methionine labeling in the
presence or absence of LMB. As shown in Fig. 1F, global
protein synthesis was not decreased by the LMB treatment.
The translation rate of most proteins remained unchanged,
and in particular one band in the 50-kDa range showed an
increased synthesis rate in response to the LMB treatment.
Together, these data implicate the ribosomal localization of
SBP2 in being important for efficient selenoprotein synthesis;
however, this does not exclude the possibility that additional
Sec incorporation factors may also be affected by the LMB
treatment.
Characterization of motifs that regulate subcellular local-
ization of SBP2. To characterize the identified motifs respon-
sible for SBP2 shuttling activity, we generated GFP-fused
deletion constructs containing either the predicted NLS-
382KKKK385 (aa 1 to 583), named NLS-GFP, or the predicted
NESs (aa 584 to 854), named NES-GFP (Fig. 2A), and ana-
lyzed the localization of the truncated proteins within cells.
Transiently expressed NLS-GFP localized almost entirely
within the nucleus of COS7 cells (Fig. 2B, left panel). In con-
trast, the NES-GFP fragment was almost exclusively cytoplas-
mic (Fig. 2B, middle panel). These results indicate that the
predicted NLS and NES domains may indeed be functional
and regulate SBP2 trafficking between the nucleus and the
cytoplasm. To ensure that cytoplasmic NES-GFP arose as a
result of NES-mediated nuclear export rather than lack of
NLS, we treated NES-GFP-expressing COS7 cells with LMB.
Similar to full-length SBP2-GFP, the NES-GFP construct ac-
cumulated in the nucleus in response to LMB treatment (Fig.
2B, right panel), suggesting that this region is responsible for
the CRM1-dependent nuclear export of SBP2 and that at least
one of the putative NESs may be functional. This fragment was
able to enter the nucleus despite the lack of sequences that
resemble a conventional NLS; therefore, its entry could be
mediated by a cryptic NLS that becomes exposed in the trun-
cated protein. Indeed, several lysine and arginine residues
which have the potential to form a cryptic NLS are present
within this region as part of the RNA binding domain. Another
possibility is that the protein enters the nucleus by piggyback-
ing on an NLS-containing binding partner.
To further define the role of the amino-terminal consensus
NLS (382KKKK385) in nuclear import of SBP2, site-directed
mutations of K383 and K384 to alanine were simultaneously
introduced in the SBP2-GFP and NLS-GFP constructs, and
their effect on SBP2 localization was analyzed in transiently
transfected COS7 cells. Inactivation of the NLS in the NLS-
GFP construct induced a partial shift of the protein localiza-
tion to the cytoplasm, the majority of cells showing equal
nuclear/cytoplasmic fluorescence (data not shown). The full-
length NLS mutant SBP2-GFP was also significantly less effi-
cient in accumulating in the nucleus than wild-type (wt) SBP2-
GFP in response to LMB treatment (Fig. 2C). Quantitation of
NLS wt or mutant SBP2-GFP in two independent experiments
(Fig. 2D) showed that after 2 h of treatment, 75% of cells
expressing the wt SBP2-GFP displayed entirely nuclear fluo-
rescence. In contrast, only 30% of NLS mutant SBP2-GFP-
expressing cells displayed entirely nuclear fluorescence and
the majority of cells showed equal nuclear/cytoplasmic fluo-
rescence. These results establish that the amino-terminal
382KKKK385 sequence is indeed a functional NLS motif that
facilitates nuclear translocation of SBP2. The partial nuclear
accumulation of the NLS mutant SBP-GFP may occur through
partial binding of the importin-/ complex, the presence of
additional NLS sequences, or, as mentioned previously, by
piggybacking on an NLS-containing binding partner.
In order to test the candidate SBP2 NES sequences for
export activity, we employed a previously described in vivo
NES assay (29) which uses a construct containing a nuclear
percentage below the fraction. (E) Western blot analysis of SBP2 distribution in nuclear and ribosomal fractions from HeLa cells treated with LMB
for 20 h. PCNA and actin were used as markers for nuclear and ribosomal loading, respectively. (F) Selenoprotein synthesis and global protein
synthesis in HeLa cells in response to LMB treatment were analyzed by 75Se and [35S]methionine labeling, respectively, followed by SDS-PAGE
and autoradiography. Densitometry analysis results showing differences (fold) were normalized to the loading of gels, as shown by Coomassie blue
(CB) staining.
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export-deficient HIV Rev protein fused to the GFP reporter
protein (Rev1.4-GFP). This fusion protein localizes within the
nuclei of cells, and active NESs are identified by their ability to
promote export of the protein when inserted between the
Rev1.4 and GFP moieties. Candidate SBP2 NES sequences
(Fig. 2E) in the Rev1.4-GFP construct were tested for export
activity in transiently transfected COS7 cells. As the Rev1.4
protein contains a strong NLS that may not be overcome by a
weak NES, cells were cotreated with Act D and cycloheximide,
to block nuclear import and protein synthesis, respectively, to
ensure that cytoplasmic fluorescence was caused by nuclear
export and not by newly synthesized protein. LMB was used in
parallel to ensure the specificity of NESs for CRM1-dependent
nuclear export. In line with our results from LMB treatment of
FIG. 2. Identification of functional NLS and NES motifs within SBP2. (A) Schematic representation of SBP-GFP fusion constructs generated
to contain the putative NLS or NES motifs. (B) Representative microscopy images of localization of the NLS-GFP and NES-GFP fusion proteins
in COS7 cells. Cells were treated with LMB (2 ng/ml) where indicated. (C) Representative microscopy images of cells expressing SBP2-GFP with
wild-type NLS (382KKKK385) or mutant (mut) NLS (382KAAK385) treated with LMB. (D) Quantitation of number of cells expressing NLS wt or
mutant SBP2-GFP with predominantly nuclear fluorescence, as a mean of two independent experiments. (E and F) An in vivo export assay to test
the functionality of the five putative candidate SBP2 NES sequences as depicted in panel E. ID, identification. (F) Subcellular localization of
functional SBP2 NESs in the Rev1.4-GFP reporter construct within untreated or Act D- or LMB-treated COS7 cells.
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both full-length and deletion constructs, we identified two
SBP2 sequences with nuclear export activity (Fig. 2F) out of
the five sequences tested. The sequence representing NES1,
634QMLSKEVDACVTDLLKELVRFQD657, had the ability
to partially shift the Rev1.4 protein to the cytoplasm in the
absence of Act D treatment, and this effect was greatly en-
hanced in treated cells (Fig. 2F, middle panels). The NES5
sequence, 756QDQFHKMVELTVAAR770, did so mainly after
Act D treatment (Fig. 2F, bottom panels), suggesting that this
may represent a weaker, albeit functional, NES. LMB treat-
ment abrogates the cytoplasmic localization of both NESs (Fig.
2F, right panels), confirming their CRM1 specificity. Together,
these results show that SBP2 contains functional NES motifs
that combined with the NLS enable its trafficking between the
nucleus and the cytoplasm via the CRM1 pathway.
Nuclear accumulation of SBP2 coincides with its oxidation
in vivo. To explore the regulation of SBP2 subcellular local-
ization further, we addressed the effects of altered intracellular
conditions such as oxidative stress on its localization. Treat-
ment of 293T or HeLa cells with oxidants such as H2O2 or
sodium selenite showed no significant changes in SBP2 protein
levels for up to 24 h post-stress imposition (data not shown),
suggesting that SBP2 is not regulated at the translational level
in response to oxidative stress. We next investigated the effect
of oxidative stress on overexpressed SBP2-GFP in transiently
transfected COS7 or 293T cells. Interestingly, oxidative stress
treatments induced the relocation of overexpressed SBP2-GFP
from the cytoplasm to the nucleus in both cell types. Figure 3A
shows nuclear accumulation of SBP2-GFP in COS7 cells
treated with H2O2 (left panel) or UVA (middle panel) and
cytoplasmic localization in untreated cells (right panel). Stress
caused by osmotic shock did not affect the cytoplasmic local-
ization of SBP2-GFP (data not shown), suggesting that oxida-
tive stress specifically induces nuclear accumulation of SBP2-
GFP. To determine if nuclear accumulation of SBP2 is
reversible, cells were treated with 100 M H2O2 for 1 h and
FIG. 3. Nuclear accumulation of SBP2-GFP in response to oxidative stress correlates with its oxidation in vivo. (A) Representative microscopy
images of SBP2-GFP localization in COS7 cells untreated and treated with H2O2 (1 mM) or UVA irradiation (10 J/m
2). Nuclei are shown by DAPI
stain (blue) (B) Graphical representation of time course analysis of SBP2-GFP subcellular distribution following H2O2 (100 M) treatment by
scoring cells for nuclear (diamond), nuclear/cytoplasmic (triangle), or cytoplasmic (square) fluorescence. (C) Determination of endogenous SBP2
redox status in vivo. 293T cells were treated with 1 mM H2O2, diamide, or sodium selenite for 2 h, and the redox status of SBP2 was analyzed using
the double-alkylation method. SBP2 was immunoprecipitated from total cell lysates, and biotinylated protein (i.e., oxidized in vivo) was detected
with HRP-conjugated streptavidin (top panel). The membrane was reprobed with anti-SBP2 antibodies as a control for protein loading between
samples (bottom panel). WB, Western blotting. (D) 293T cells were treated with sodium selenite to induce oxidative (Ox.) stress, and SBP2
migration was analyzed by Western blotting as described in Fig. 1, under nonreducing and reducing conditions. Sodium selenite concentrations are
indicated above each lane. Cross-reacting bands on the same membranes show gel loading and no migration differences.
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SBP2-GFP localization was determined over a 24-h period
after release from H2O2. Nuclear localization of SBP2-GFP
was maximal at 4 h after treatment, and at later time points (12
and 24 h), cells with mainly cytoplasmic fluorescence were
observed, suggesting that nuclear accumulation of SBP2-GFP
occurred in a reversible manner (Fig. 3B). Similar effects were
observed after UVA treatments at doses of 5, 10, or 20 J/m2.
We postulated that nuclear accumulation of SBP2 could be
triggered in at least two different ways: by phosphorylation via
the stress-induced mitogen-activated protein kinase pathway
or by direct oxidation of critical cysteine residues. To test the
former model, we treated SBP2-GFP-transfected COS7 cells
with either the stress-activated protein kinase (SAPK/p38)-
specific inhibitor SB203580 (3) or with the Janus kinase (JNK)
specific inhibitor SP600125 (4) prior to H2O2 treatment. These
treatments did not prevent nuclear accumulation of SBP2-GFP
(data not shown). Thus, phosphorylation, at least if dependent
on the p38 or the JNK protein kinases, does not seem to be the
cause of nuclear accumulation of SBP2-GFP in response to
oxidative stress. In addition, we did not observe any SBP2
mobility changes during reducing electrophoresis following ox-
idative stress treatments (Fig. 3D, bottom panel), further sug-
gesting that phosphorylation events are not the likely cause of
nuclear accumulation of SBP2.
To address the hypothesis that nuclear accumulation of
SBP2 may be caused by direct cysteine oxidation, we investi-
gated the redox state of endogenous SBP2 in untreated cells
and in cells exposed to oxidative stress. The two-step alkylation
assay (7) was employed using biotin-conjugated IAM (BIAM)
as an alkylating agent for detecting potentially oxidized forms
of SBP2. As expected, in unstressed cells SBP2 is present in a
reduced state, as indicated by the absence of any BIAM-con-
jugated SBP2 (Fig. 3C, lane 1). Interestingly, all oxidants in-
duced oxidation of SBP2 in vivo, as determined by the pres-
ence of BIAM-conjugated SBP2 in protein samples obtained
from treated cells (Fig. 3C, lanes 2, 3, and 4). The treatments
caused various levels of oxidation of SBP2; the greatest effect
was observed in selenite-treated samples. This may reflect the
strong oxidizing properties of selenite manifested through the
depletion of both the buffering GSH pool and antioxidant
enzymes (49). In vivo oxidation of SBP2 occurred at the time
point at which SBP2 was first detected in the nucleus after
stress treatment, providing further evidence of a redox-regu-
lated nuclear accumulation of SBP2. Moreover, nonreducing
SDS-PAGE revealed the formation of oxidation-induced mo-
bility alterations of SBP2, which was noticeable by the appear-
ance of an additional band in samples treated with selenite at
a concentration of 100 M or higher (Fig. 3D), indicating the
formation of oxidized forms of the protein in response to
oxidant treatment. A cross-reactive band detected on the same
blot does not display any similar changes, suggesting that the
modifications are specific to SBP2. Importantly, this shift was
eliminated by reducing conditions (Fig. 3D, bottom panel),
implying that the mobility change is caused by direct oxidation
of the protein. The poor detection of SBP2 in samples treated
with the highest concentration of selenite treatment (Fig. 3D,
top panel, last lane) may be a result of masking of antibody
epitope in a highly oxidized protein. Another possibility is that
high concentration of selenite causes degradation of SBP2,
because in a reducing gel smaller amounts of SBP2, but not
cross-reactive proteins, are observed. Collectively, these results
suggest that SBP2 is a redox-sensitive protein and direct redox
modification occurs within SBP2 in response to oxidative
stress.
The carboxy-terminal region of SBP2 mediates its nuclear
retention in response to oxidative stress. To further define the
mechanism involved in redox regulation of SBP2, we initially
applied an in silico method (23) to predict redox-sensitive
cysteine residues within SBP2 using the web-based server
at http://manaslu.aecom.yu.edu/cysredox.html. Four cysteines
(C633, C644, C691, and C698) with putative redox properties
were predicted using this method; they were located within the
carboxy-terminal region of SBP2. Further analysis of SBP2
amino acid sequence revealed that SBP2 contains 12 cysteines
in total and that 7 of these, including the ones predicted in
silico, are present in a cluster within the C-terminal region of
SBP2. Interestingly, this cluster overlaps with the RNA binding
domain and the identified NESs and may constitute a redox-
sensitive cysteine-rich domain (CRD) with potential to regu-
late SBP2 localization and/or function. This domain is remi-
niscent of the CRD identified within the Yap-1 transcription
factor, which was shown to be directly involved in regulating
Yap-1 transactivation activity in response to oxidative stress
(39). The location of the CRD and other cysteine residues
within the SBP2 amino acid sequence is schematically pre-
sented in Fig. 4A.
To explore the role of CRD in regulation of SBP2, its con-
tribution to the nuclear sequestration of SBP2 in response to
oxidative stress was investigated using the NES-GFP construct,
which encompasses the CRD as well as the RNA binding
domain and the identified NESs. As predicted, we found that
oxidative stress imposed by H2O2 (Fig. 4B, middle panel),
diamide, and sodium selenite (data not shown) caused nuclear
accumulation of the otherwise cytoplasmic NES-GFP (Fig. 4B,
left panel), suggesting that the CRD may be mediating nuclear
retention of SBP2 by masking the NES through disulfide bond
formation. Consistently, treatment with the irreversible thiol
alkylator IAM induced nuclear retention of NES-GFP (Fig.
4B, right panel), confirming that nuclear export requires the
presence of free cysteine residues. Similar results using IAM
were observed for the full-length SBP2-GFP (data not shown).
Together, these results suggest that cysteine residues within
the CRD are directly involved in regulation of SBP2 nuclear
export. The location of C644 within NES 1 identified further
supports this model.
Oxidized SBP2 is reduced by the thioredoxin system in vitro.
To assess direct redox-dependent modifications of SBP2, we
conducted a detailed in vitro biochemical analysis of the His-
tagged, C-terminal region of SBP2 (NES-His6 aa 584 to 854).
Nonreducing SDS-PAGE and thiol-specific alkylation with the
fluorescent probe 5-iodoacetofluorescein (5-IAF) revealed the
existence of oxidized, faster-migrating NES-His6 monomer
(Fig. 5A, left panel). Likewise, an oxidized dimer migrating at
double the molecular mass and oxidized protein aggregates
were detected. Moreover, the absence of fluorescent signal
under nonreducing conditions confirms the existence of NES-
His6 in an oxidized state. Reduction with DTT or the physio-
logical reductant GSH resulted in complete alkylation of the
protein, as indicated by the strong fluorescent labeling and the
electrophoretic mobility retardation (Fig. 5A, right panel).
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Dimerization of NES-His6 was further confirmed by electro-
spray ionization tandem mass spectrometry (ESI MS/MS)
(data not shown), which demonstrated that in the presence of
DTT, most of the protein was detected in the monomeric form
(31,693 Da). However, in the absence of reductant, the dimeric
form (63,385 Da) prevailed. Dimerization of SBP2 has previ-
ously been reported using recombinant proteins (1, 42); how-
ever, since then, a more recent study indicated that dimeriza-
tion of SBP2 was an artifact caused by the tag used to purify
the protein (38). The data presented here clearly demonstrate
that the C-terminal region of SBP2 is able to form dimers
in the absence of reductant and suggest that SBP2 has the
potential to dimerize under conditions of oxidative stress.
Whether this occurs in vivo and whether it has any implications
for SBP2 Sec incorporation function would be interesting top-
ics of future investigations.
Quantitative determination of thiols and disulfide bonds in
SBP2 using the DTNB method (33) revealed the presence of
one cysteine in its thiol form, without prior reduction. DTT
reduction followed by immediate processing in aerobic solu-
tions leads to the detection of five free thiols, and incubation in
aerobic solutions for as brief as 1 to 2 min leads to a rapid
reoxidation to the fully oxidized form. Detection of seven thi-
ols was only measurable following preparation under anaero-
bic conditions, indicating that the NES-His6 protein is ex-
tremely sensitive to oxidation.
We next sought to determine whether the oxidation of cys-
teines within the CRD of SBP2 may have an in vivo relevance
in terms of their reversibility. We tested whether NES-His6
could act as a substrate of the major cellular protein-disulfide
reductase system comprising thioredoxin (Trx), thioredoxin re-
ductase (TR), and NADPH (34). Since Trx and TR are both
disulfide-reducing enzymes, we determined that oxidized NES-
His6 is not a direct substrate of TR (data not shown). In
contrast, oxidized NES-His6 is efficiently reduced by Trx, as
shown in a comparative NADPH oxidation assay with insulin,
an efficient Trx substrate, at various concentrations of sub-
strates. The results of three independent kinetic measurement
experiments are presented in Fig. 5C. Direct redox reactions
between NES-His6 disulfides and Trx dithiols were also con-
firmed by apparent differences in the fluorescence spectra of
reduced E. coli Trx upon incubation with oxidized NES-His6
(Fig. 5D). These results not only identify SBP2 as a novel
substrate of the Trx system but also imply that SBP2 redox
status in vivo may be modulated by the Trx system.
SBP2 forms glutaredoxin-reversible glutathione-mixed di-
sulfides. In addition to the Trx system, GSH and Grx represent
another essential cellular redox-controlling system (21). This
system, comprising NADPH, GSH, GR and Grx, acts in con-
cert with the Trx system in maintaining the intracellular redox
balance. Although they have overlapping functions, one dis-
tinct feature between the two systems is the higher specificity
of Grx for glutathionylated protein disulfides, also referred to
as GSH-mixed disulfides (48). Protein S glutathionylation is
believed to be the predominant reversible oxidative modifica-
tion during oxidative stress, but also acts as a regulatory mech-
anism during normal metabolism (25). To address whether
SBP2 can be modified by glutathionylation, DTT-reduced
NES-His6 was incubated with oxidized GSH (GSSG) and the
products were analyzed by nonreducing SDS-PAGE and West-
ern blotting with anti-GSH antibodies. Interestingly, approxi-
mately half the total NES-His6 protein formed GSH-mixed
disulfides, evident by slower electrophoresis migration similar
to that of the IAM-alkylated protein (Fig. 6A) and recognition
by the anti-GSH antibodies, suggesting that glutathionylation
may represent an additional means of regulation of SBP2. To
address the significance of glutathionylated SBP2, we investi-
gated its reversibility using the Grx system, which has a high
specificity in reducing glutathionylated protein substrates. En-
zyme kinetic measurements showed that GSSG-oxidized NES-
His6 was approximately fivefold more efficiently reduced by
FIG. 4. Carboxy-terminal region of SBP2 contains a CRD that can
modulate SBP2 subcellular localization. (A) Cysteine residues and
their distribution within SBP2 are schematically indicated. Cysteines
within the CRD are shown in boldface. The amino acid sequence of
the C-terminal SBP2 region (NES-GFP) shows the location of the
RNA binding domain (italic), the NESs (underlined), and the cysteines
within the CRD. (B) Representative microscopy images of COS7 cells
expressing the NES-GFP, with or without H2O2 (100 M) or IAM (1
mM) treatment. DAPI stain shows the nuclei, and arrows indicate
transfected cells.
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human Grx1 than oxidized NES-His6 (Fig. 6B). Consistent
with these data, MS/MS analysis by nano-ESI–quadrupole–
time of flight (TOF) mass spectrometry identified the existence
of a single or double GSH-linked NES-His6 protein (data not
shown). Moreover, MALDI-TOF analysis of endo-Glu-C-di-
gested GSSG-oxidized NES-His6 identified two glutathionyl-
ated sites (Fig. 6C), at positions C691 or C698 and C803. The
close proximity between C691 and C698 did not allow the de-
termination of the exact GSH-bound cysteine residue. Collec-
tively, these results demonstrate that SBP2 forms reversible
GSH-mixed disulfides in vitro and identify SBP2 as a novel
substrate of human Grx1, suggesting that glutathionylation of
SBP2 may have a significant regulatory role in vivo.
SBP2 is required for Sec incorporation in vivo and regulates
selenoprotein synthesis during oxidative stress. Several lines
of evidence from in vitro and cell culture models have indi-
cated SBP2 as the central regulator of selenoprotein synthesis.
However, conclusive evidence in vivo has so far not been pro-
vided. Recently, using siRNA technology, two novel factors,
Secp43 and the soluble liver antigen proteins, were shown to be
required for selenoprotein biosynthesis (55) in cell lines, and
the same technology was used in the present study to charac-
terize the cellular phenotype of SBP2-depleted cells.
First, we undertook a comparative analysis of cellular sur-
vival following H2O2 and selenite exposure in SBP2-depleted
(transfected with SBP2 siRNA) and control cells (transfected
with GFP siRNA). A number of target siRNA sequences
within SBP2 were tried, and only a partial knockdown of SBP2
(50%) was achieved in cells (Fig. 7A), suggesting either neg-
ative selection against SBP2 depletion or SBP2 mRNA is pro-
tected against the siRNA effect. Partial depletion of SBP2 in
HeLa cells had no effect on cellular viability when propagated
under normal conditions. On the other hand, H2O2 and so-
dium selenite stimulated a dose-dependent decrease in cell
survival and SBP2-depleted cells exhibited significantly greater
sensitivity to H2O2 and selenite exposure than control cells, as
FIG. 5. Redox-sensitive cysteine residues within carboxy-terminal SBP2 act as a substrate of the thioredoxin system. (A) Analysis of the redox
state of His6-tagged C-terminal region of SBP2 (NES-His6) by alkylation with the fluorescent thiol alkylator 5-IAF during nonreducing (lanes 1
and 1) or reducing (lanes 2 and 2 and 3 and 3) SDS-PAGE. The redox states of the protein as reduced (red) or oxidized (ox) monomers, dimers,
and oligomers are indicated by arrows. Loading is shown by Coomassie blue staining, and 5-IAF incorporation is shown as detected with UV light
(right panel). (B) Fifty microliters of NES-His6 (63 M) pretreated as indicated was denatured in 450 l 8 M guanidinium hydrochloride (Gn-HCl)
containing DTNB. The thiol content was analyzed by measuring the absorbance at 412 nm and calculated using the extinction coefficient of
thionitrobenzoate (TNB) at 412 nm. (C) Graphical representation of a comparative thioredoxin activity assayed using insulin, NES-His6, or GSSG
as the substrate. Kinetics were measured in a master mix containing 50 mM Tris-HCl, pH 7.5, 2 mM EDTA, 0.1 mg/ml bovine serum albumin, 50
nM TR, 200 M NADPH, and 5 M Trx. (D) Changes in fluorescence emission spectra of E. coli Trx reduced (solid line) and oxidized by
NES-His6 (dashed line).
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FIG. 6. Distinct SBP2 carboxy-terminal cysteines form glutathione-mixed disulfides that are reduced by human glutaredoxin 1 (hGrx1). (A) Reduced
NES-His6 was incubated with GSSG or IAM. Complexes were resolved by nonreducing SDS-PAGE. Western blot (WB) analysis using anti-His
antibodies (top panel) shows the different redox forms of NES-His6: oxidized (ox) or reduced (red) monomer and oxidized dimer. Reprobing with
anti-GSH antibodies (bottom panel) confirmed glutathionylated protein (NES-His6-S-SG). (B) Reduction of glutathionylated NES-His6-S-SG versus
oxidized NES-His6-S-S by hGrx1. Kinetics were measured in a solution containing 50 mM Tris-HCl, pH 7.5, 2 mM EDTA, 0.1 mg/ml bovine serum
albumin, 6 g/ml glutathione reductase, 200 M NADPH, 10 M NES-His6 or glutathionylated NES-His6, and the indicated concentration of hGrx1.
(C) MALDI-TOF analysis of endoproteinase-Glu-C-digested GSSG-oxidized NES-His6. Peaks representing peptides encompassing glutathionyl-
ated cysteine residues C691 or C698 and C803, their amino acid sequences, and molecular masses are outlined in the bottom panels.
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evidenced by reduced survival at most dose points (Fig. 7A). In
order to investigate the possible contribution of selenoprotein
synthesis to enhanced sensitivity of SBP2-depleted cells to ox-
idative stress, we compared the effect of H2O2 on Sec incor-
poration in SBP2-depleted and control cells by 75Se labeling.
We found a modest decrease in Sec incorporation in un-
treated, SBP2-depleted HeLa cells (Fig. 7B, lanes 1 and 3) with
an 1.5-fold decrease in the low-molecular-weight selenopro-
teins and an 1.3-fold decrease in TR, correlating with the
partial effect of siRNA on SBP2 levels. To address the effects
of oxidative stress, we initially monitored Sec incorporation in
H2O2-treated HeLa cells by
75Se labeling, and, unexpectedly,
we observed a general decrease in selenoprotein synthesis dur-
ing a time course experiment in stressed cells at several time
points tested (data not shown), suggesting a compromised
translation process. Importantly, H2O2 treatment combined
with siRNA-mediated depletion of SBP2 showed a significant
decrease in Sec incorporation (Fig. 7B, lanes 2 and 4), with an
3.5-fold decrease in 75Se labeling of the low-molecular-
weight selenoproteins and an 1.8-fold decrease in TR (55
kDa) labeling. These results provide for the first time direct
evidence for the requirement of SBP2 for Sec incorporation in
FIG. 7. SBP2 is required for incorporation of Sec into selenoproteins in vivo. (A and B) HeLa cells were transfected with SBP2 siRNA (siSBP2)
or GFP siRNA (siGFP) as a control and incubated for 72 h. (A) Cell viability assay of SBP2-depleted or control cells in response to oxidative stress
caused by H2O2 or sodium selenite. Western blot analysis of SBP2 protein levels was performed as described in the legend to Fig. 1 (bottom
panels). Actin was used as a loading control. (B) Autoradiography of SBP2-depleted or control cells labeled with 75Se with or without prior
treatment with H2O2. Coomassie staining shows the gel loading. Shown are the densitometry signal intensity for TR at 55 kDa (top panel and
graph) and the low-molecular-weight (MW) selenoproteins (middle panel and graph).
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vivo. The increased sensitivity toward oxidative injury in SBP2-
depleted cells may therefore arise as a direct consequence of
the decreased selenoprotein synthesis capacity in these cells,
suggesting a vital role of SBP2 in the protection against oxi-
dative stress.
DISCUSSION
In spite of the progress that has been made in delineating
the mechanism of Sec insertion in mammalian systems, a num-
ber of central questions remain to be answered: in particular,
the molecular events that regulate this process in its entirety
and the individual roles played by its components. In this study,
we have characterized the regulation of SBP2 subcellular lo-
calization and function and showed for the first time that SBP2
is required for Sec incorporation in vivo. The findings pre-
sented included identification of functional NLS and CRM1-
dependent NES motifs facilitating a dynamic subcellular local-
ization of SBP2, as well as redox regulation of SBP2. Several
models for Sec incorporation have been put forward in the
literature. The most recent and well-validated model proposed
that SBP2 is stably bound to the ribosomes, except during the
Sec delivery to the ribosomal A site, when its release facilitates
the delivery of the eEFSec-tRNASec complex and incorpora-
tion of Sec (9, 38). Our data agree with this model and in
addition support earlier proposed models by demonstrating
that SBP2 subcellular localization is not solely confined to
ribosomal sites; in fact, SBP2 shuttles between the nucleus and
the cytoplasm in a motif-regulated manner. We propose that
SBP2 translocates through the nuclear compartment either
immediately after its synthesis or during its release from the
ribosome during the process of Sec incorporation. Within the
nucleus, the dominant NES is exposed, which in turn triggers
its rapid export to the cytoplasm dependent on the presence of
functional CRM1 (Fig. 8A). A question that remains unan-
swered, however, is the role of nuclear SBP2. It was previously
suggested that SBP2 may enter the nucleus to associate with
selenoprotein-encoding mRNAs and facilitate their transport
to the cytoplasm for translation. mRNAs are generally ex-
ported from the nucleus as ribonucleoprotein complexes, in-
cluding RNA binding proteins and transport factors (57). Be-
cause translation of selenoproteins requires unique factors, the
transport of their cognate mRNAs from the nucleus may in-
volve interactions with some of these factors prior to their
arrival at the ribosomal sites. We showed that SBP2 contains
NLS and NES motifs to perform such functions; consequently,
its shuttling properties may be involved in transport of mRNAs
and be directly linked to its Sec incorporation function. Inter-
estingly, the NES motifs are located close to the RNA binding
domain, raising the possibility that their availability for CRM1
binding may be related to conformational changes caused by
the binding of SBP2 to SECIS elements. In that respect, inhi-
bition of transcription using Act D for up to 24 h did not lead
to nuclear retention of overexpressed SBP2-GFP (data not
shown), suggesting that binding of mRNAs may not be a pre-
requisite for nuclear export of SBP2. Since SBP2 is also known
to associate with rRNA (13, 38), we cannot exclude a possible
role of this association in the nuclear export of SBP2. Alter-
natively, SBP2 nuclear localization may serve additional func-
tions, possibly unrelated to Sec incorporation, which should be
an interesting topic for future studies. Our data, together with
previous reports (13, 38), provide strong evidence that SBP2 is
predominantly associated with the ribosomes and its depletion
from ribosomes significantly decreased selenoprotein synthe-
sis, while global protein synthesis was unaffected by similar
conditions, suggesting that a ribosome-associated pool of SBP2
directs the synthesis of selenoproteins.
Furthermore, we have also identified a novel link between
the redox status of SBP2 and its intracellular localization. As
several selenoproteins are directly involved in the antioxidant
defense mechanism and detoxification of reactive oxygen spe-
cies, an increase in selenoprotein expression in response to
oxidative stress was expected. Paradoxically, however, a clear
reduction in selenoprotein synthesis after oxidative stress was
observed, indicating that translation ceased during oxidizing
conditions within the cytoplasm. Analysis of data from a pre-
vious study (46) revealed no changes in mRNA transcript lev-
els of 12 selenoprotein genes under similar stress conditions,
suggesting that the transcriptional response is not affected.
Therefore, it is likely that the reduced protein levels observed
herein are due to inhibition at the level of translation. In
accordance with these observations, a growing body of evi-
dence suggests that global protein translation is reduced in
response to most types of cellular stresses, allowing the cells to
conserve resources and to initiate a reconfiguration of gene
expression to effectively manage stress conditions (32, 52).
These events are mainly regulated through inhibitory phosphor-
ylation of the global initiation factor 2 (eIF-2) (17, 22), and
simultaneously, a switch to the cap-independent, internal ribo-
somal entry site (IRES)-mediated translation occurs to allow
production of a select set of proteins required for cell survival,
proliferation, or death, depending on the severity of the stress
(22, 47). Transient stress conditions (such as used in this study)
were shown to favor the translation of prosurvival IRES ele-
ments such as those present in the mRNA of the antiapoptotic
molecule XIAP, whereas severe stress supports translation of
prodeath IRES elements such as the proapoptotic molecule
Apaf-1 (47). To date, no selenoprotein mRNAs have been
shown to contain IRES elements within their mRNAs. It is
thus possible that their decreased translation may reflect the
absence of such elements. Moreover, since Sec is an extremely
redox-sensitive amino acid, it seems feasible for its translation
to be restrained by oxidizing conditions. It would be interesting
to investigate how tRNA[Ser]Sec biosynthesis is affected by ox-
idative stress, as tRNA[Ser]Sec availability is believed to be a
main regulatory point in selenoprotein synthesis (28). Since
the requirement of SBP2 for selenoprotein synthesis in vivo
was demonstrated, we propose that translational inhibition
during oxidative stress is mediated through direct oxidation
of SBP2 and by its sequestration from the ribosomes into the
nuclear compartment. Its nuclear retention may be medi-
ated by oxidized cysteines and masking of the NES in a
manner that interferes with CRM1 transport and possibly
also mRNA binding (Fig. 8B). We hence propose that SBP2
Sec incorporation function is directed by the ribosome-as-
sociated pool of SBP2, which is regulated by its redox state.
Accordingly, several translation factors form inactivating
disulfide linkages within cells exposed to oxidative stress
(14), and in yeast, H2O2 stress causes a rapid, but reversible
inhibition of protein synthesis mediated by glutathionylation
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of translation factors (48). Since SBP2 is able to form GSH-
mixed disulfides in vitro, it is tempting to speculate that
glutathionylation, by introducing a steric hindrance, may
have an inhibitory effect on SBP2 Sec incorporation func-
tion. The reversibility of oxidative modifications in vitro by
Trx and Grx led us to speculate that nuclear export of SBP2
and its relocation to the ribosomes during the cell recovery
from oxidative stress are dependent on the reducing capac-
ity of these two systems (Fig. 8C), which also accumulate in
the nucleus in response to stress (30, 31).
In conclusion, this study provides a novel level of regula-
tion of selenoprotein synthesis through redox regulation of
SBP2 and will most certainly serve as a platform for future,
more elaborate studies to understand the different aspects
of SBP2 redox regulation, such as ribosomal localization and
RNA binding, as well as the regulation by glutathionylation.
FIG. 8. A proposed model for the regulation of SBP2 subcellular localization and function. (A) Under normal conditions, the majority of the
SBP2 pool is localized within the cytoplasm, at ribosomal sites, where it functions as part of the Sec incorporation complex. SBP2 contains
functional NLS that mediates its nuclear translocation to potentially bind SECIS-containing mRNAs. This may trigger exposure of the NES, which
would lead to rapid nuclear export of SBP2 via the CRM1 pathway and restore the ribosomal steady-state levels of SBP2. (B) During oxidative
stress, redox-sensitive cysteine residues within SBP2 become oxidized to disulfide linkages (S-S) and/or form glutathione-mixed disulfides (S-SG),
leading to a conformational change, disrupting its ribosomal localization and triggering its nuclear translocation. The lack of sufficient reducing
equivalents maintains SBP2 in an oxidized state which masks the NES, inhibiting its export and leading to its nuclear retention and inhibition of
selenoprotein synthesis. (C) During the cell recovery phase, Trx and Grx relocate to the nucleus and reduce SBP2, leading to exposure of the NES
and promoting CRM1-dependent nuclear export. In the cytoplasm, reassembly of SBP2-containing translationally active ribosomal complexes
takes place and synthesis of selenoproteins can commence.
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As is apparent from the data presented herein, regulation of
SBP2 localization and function is more complicated than
previously thought and most likely requires multiple events
as well as several pathways involving Trx and Grx, all work-
ing in concert.
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